Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by ARK Investment Management LLC

ARK Investment Management LLC lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 68.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 437,403 shares of the company’s stock after acquiring an additional 177,565 shares during the period. ARK Investment Management LLC owned 0.11% of Moderna worth $43,500,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MRNA. First Pacific Financial acquired a new stake in shares of Moderna during the third quarter valued at $27,000. ICA Group Wealth Management LLC acquired a new stake in shares of Moderna during the fourth quarter valued at $27,000. Stonebridge Capital Advisors LLC boosted its stake in shares of Moderna by 79.1% during the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after acquiring an additional 125 shares during the last quarter. Ancora Advisors LLC boosted its stake in shares of Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after acquiring an additional 96 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC boosted its stake in Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after buying an additional 180 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO James M. Mock sold 772 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $109.75, for a total transaction of $84,727.00. Following the completion of the transaction, the chief financial officer now owns 3,632 shares in the company, valued at approximately $398,612. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 647 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,021 shares of company stock worth $5,211,442. 15.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on MRNA shares. Canaccord Genuity Group started coverage on Moderna in a research note on Wednesday, November 29th. They issued a “hold” rating and a $82.00 price target on the stock. Canaccord Genuity Group raised their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. HSBC reissued a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a report on Tuesday, January 2nd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a report on Friday, February 23rd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $129.82.

Moderna Price Performance

MRNA stock opened at $110.59 on Thursday. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $163.24. The stock’s 50 day moving average is $98.79 and its two-hundred day moving average is $93.49. The company has a market capitalization of $42.34 billion, a PE ratio of -8.91 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business’s revenue was down 44.9% on a year-over-year basis. During the same quarter last year, the firm earned $3.61 EPS. Analysts predict that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.